US2017079999A1PendingUtilityA1
Unitary pharmaceutical dosage form
Assignee: BRISTOL-MYERS SQUIBB & GILEAD SCIENCES LLCPriority: Jun 13, 2005Filed: Dec 6, 2016Published: Mar 23, 2017
Est. expiryJun 13, 2025(expired)· nominal 20-yr term from priority
Inventors:Terrence C. DahlMunir A. HussainRobert A. LipperRobert L. JerzewskiMark M. MenningReza OliyaiTaiyin Yang
A61P 31/18A61P 31/12A61P 31/00A61K 31/513A61K 31/535A61K 31/683A61K 9/209A61K 9/2054A61K 31/522A61K 31/551A61K 9/2077A61K 31/536A61K 31/675A61K 9/20
53
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
Claims
exact text as granted — not AI-modified1 . A composition comprising tenofovir DF and a surfactant whereby the surfactant is in a stabilizing configuration with the tenofovir DF.
2 - 30 . (canceled)Join the waitlist — get patent alerts
Track US2017079999A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.